# Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)

> **NCT04655625** · PHASE2,PHASE3 · COMPLETED · sponsor: **AnGes, Inc.** · enrollment: 500 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Group A (AG0302-COVID19)
- **BIOLOGICAL:** Group A (Placebo)
- **BIOLOGICAL:** Group B (AG0302-COVID19)
- **BIOLOGICAL:** Group B (Placebo)

## Key facts

- **NCT ID:** NCT04655625
- **Lead sponsor:** AnGes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-23
- **Primary completion:** 2021-04-02
- **Final completion:** 2022-02-01
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2022-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655625, "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04655625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*